15,225 results match your criteria Hepatic Carcinoma Primary


[The third-generation sequencing combined with targeted capture technology for high-resolution HLA typing and MHC region haplotype identification].

Yi Chuan 2019 Apr;41(4):337-348

Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China.

The high-resolution and accurate typing of human leukocyte antigen (HLA) is of great significance for the study of tissue matching in organ transplantation and the correlation between HLA and disease. In this study, the peripheral blood of 12 patients with primary hepatocellular carcinoma was used to compare the advantages and disadvantages of the next- and third-generation sequencing technology for high-resolution HLA typing. In addition, probe capture technology was used to capture the MHC region of YH and HeLa standard cell lines, and a primary hepatocellular carcinoma patient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.16288/j.yczz.18-282DOI Listing

Recent advances in PET probes for hepatocellular carcinoma characterization.

Expert Rev Med Devices 2019 Apr 16. Epub 2019 Apr 16.

a Department of Nuclear Medicine , Santa Maria Goretti Hospital , Via Canova 3, 04100 Latina , Italy.

Introduction: Positron Emission Tomography (PET) with F-fluorodeoxyglucose (FDG) presents some limitations for imaging of hepatocellular carcinoma (HCC), the most common primary hepatic malignancy. Areas covered: The authors discuss the accuracy and limitations of FDG for HCC detection. Then, authors examine the recent advances in PET tracers other than FDG for the biological and prognostic characterization of HCC such as C-acetate, C-choline and its F-labeled derivatives. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17434440.2019.1
Publisher Site
http://dx.doi.org/10.1080/17434440.2019.1608817DOI Listing
April 2019
1 Read

Angiosarcoma of the Liver: Clinicopathologic Features and Morphologic Patterns.

Am J Surg Pathol 2019 May;43(5):581-590

Division of Anatomic Pathology, Mayo Clinic, Rochester, MN.

Angiosarcoma is a rare malignant neoplasm of the liver. The various morphologic patterns seen with angiosarcomas of the liver have not been systematically studied and their recognition remains a major diagnostic challenge. In order to provide more comprehensive data on the morphologic patterns, angiosarcomas that had been diagnosed between 1996 and 2016 at a large medical referral center were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000001228DOI Listing
May 2019
3 Reads

A Rare Case of Primary Endometrial Hepatoid Adenocarcinoma on 18F-FDG PET/CT.

Clin Nucl Med 2019 Apr 12. Epub 2019 Apr 12.

From the Departments of Nuclear Medicine and.

Primary endometrial hepatoid adenocarcinoma is a rare tumor. We present a case of a 64-year-old woman with vaginal bleeding for 2 months and a markedly elevated serum α-fetoprotein of 3931 ng/mL. Hysteroscopic segmental curettage revealed endometrial adenocarcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002538DOI Listing
April 2019
2 Reads

Hepatocellular carcinoma surveillance: An evidence-based approach.

World J Gastroenterol 2019 Apr;25(13):1550-1559

Division of Gastroenterology and Hepatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, United States.

Hepatocellular carcinoma (HCC) makes up 75%-85% of all primary liver cancers and is the fourth most common cause of cancer related death worldwide. Chronic liver disease is the most significant risk factor for HCC with 80%-90% of new cases occurring in the background of cirrhosis. Studies have shown that early diagnosis of HCC through surveillance programs improve prognosis and availability of curative therapies. Read More

View Article

Download full-text PDF

Source
https://www.wjgnet.com/1007-9327/full/v25/i13/1550.htm
Publisher Site
http://dx.doi.org/10.3748/wjg.v25.i13.1550DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452232PMC
April 2019
3 Reads

Survival comparison between primary hepatic neuroendocrine neoplasms and primary pancreatic neuroendocrine neoplasms and the analysis on prognosis-related factors.

Hepatobiliary Pancreat Dis Int 2019 Apr 5. Epub 2019 Apr 5.

Division of Hepatobiliary Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. Electronic address:

Background: Primary hepatic neuroendocrine neoplasms (PHNENs) are extremely rare and few articles have compared the prognosis of PHNENs with other neuroendocrine neoplasms (NENs). This study aimed to investigate the different prognosis between PHNENs and pancreatic NEN (PanNENs) and evaluate the relevant prognosis-related factors.

Methods: From January 2012 to October 2016, a total of 44 NENs patients were enrolled and divided into two groups according to the primary tumor location which were named group PHNENs (liver; n = 12) and group PanNENs (pancreas; n = 32). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hbpd.2019.03.009DOI Listing

Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.

Biomed Pharmacother 2019 Apr 10;114:108864. Epub 2019 Apr 10.

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, PR China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, 110 Xiangya Road, Changsha 410078, PR China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, 110 Xiangya Road, Changsha 410078, PR China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, PR China. Electronic address:

Hepatocellular carcinoma (HCC) prognosis remains dismal due to postsurgical recurrence and distant metastasis. Therefore, novel prognostic biomarkers and therapeutic targets for HCC therapy are urgently needed to improve the survival of liver cancer patients. Our evidence suggests that SLC46A3 (the gene solute carrier family 46 (sodium phosphate), member 3) is a member of the SLC46 family and has a potential role in the progression and treatment of HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2019.108864DOI Listing
April 2019
2.023 Impact Factor

Association of Tumor Grade With Long-Term Survival in Patients With Hepatocellular Carcinoma After Liver Transplantation.

Authors:
Jun Zhao J Mao W Li

Transplant Proc 2019 Apr 9;51(3):813-819. Epub 2019 Jan 9.

Department of Liver Surgery & Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China.

Background: Association of tumor grade and the prognosis of hepatocellular carcinoma (HCC) patients after liver transplantation (LT) had not been clearly illustrated. The objective of the current study was to investigate the impact of tumor grade on the long-term survival of patients with HCC receiving LT.

Methods: Data from Surveillance, Epidemiology, and End Results Program (SEER) 18 registry for 2004-2015 was extracted for the present study. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00411345183144
Publisher Site
http://dx.doi.org/10.1016/j.transproceed.2018.12.033DOI Listing
April 2019
2 Reads

Effect of Liver Disease Etiology on ROTEM Profiles in Patients Undergoing Liver Transplantation.

Transplant Proc 2019 Apr 9;51(3):783-789. Epub 2019 Jan 9.

Department of Anaesthetics, Critical Care and Pain Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK.

Background: Coagulation abnormalities in liver transplant patients are complex and may be related to the underlying liver disease. We evaluated the effects of disease etiology on whole-blood rotational thromboelastometry (ROTEM; Pentapharm GmbH, Munich, Germany) profile and association with thrombotic complications following liver transplantation.

Methods: Analysis of perioperative data from patients undergoing liver transplantation between January 1, 2012 and December 31, 2016. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00411345183131
Publisher Site
http://dx.doi.org/10.1016/j.transproceed.2018.12.030DOI Listing
April 2019
1 Read

Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection.

Hepatol Commun 2019 Apr 8;3(4):493-503. Epub 2019 Feb 8.

Division of Gastroenterology and Hepatology Stanford University Medical Center Palo Alto CA.

Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel glycoprotein biomarker that correlates with liver fibrosis. It has been investigated in East Asian populations as a hepatocellular carcinoma (HCC) biomarker. We assessed M2BPGi as an HCC biomarker in an ethnically diverse cohort of patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep4.1321DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442699PMC
April 2019
1 Read

Treatment strategies for locally advanced hepatocellular carcinoma.

Transl Gastroenterol Hepatol 2019 18;4:12. Epub 2019 Feb 18.

Digestive Surgery Division, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil.

Liver cancer ranks fifth in incidence and fourth in overall cancer-related mortality, with approximately 854,000 new cases and 810,000 deaths per year worldwide. Hepatocellular carcinoma (HCC) accounts for 90% of these cases, and, over time, both the incidence and mortality of this cancer have been rising in many regions. Several staging systems are used to assess the extent of primary tumor, presence of metastasis, and underlying liver disease, and thereby aid in the definition of treatment strategies and prognosis for these patients. Read More

View Article

Download full-text PDF

Source
http://tgh.amegroups.com/article/view/4893/html
Publisher Site
http://dx.doi.org/10.21037/tgh.2019.01.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414334PMC
February 2019
3 Reads

Prospective Study of Isolated Recurrent Tumor Re-irradiation With Carbon-Ion Beams.

Front Oncol 2019 27;9:181. Epub 2019 Mar 27.

Gunma University Heavy Ion Medical Center, Maebashi, Japan.

To perform a prospective study to evaluate the efficacy and safety of isolated recurrent tumor re-irradiation with carbon-ion radiotherapy (RT). The inclusion criteria were clinically proven recurrent tumors, measurable by computed tomography or magnetic resonance imaging, patients ≥ 16 years old, performance status scores between 0 and 2, isolated tumor at a previously irradiated site, and a life expectancy > 6 months. The exclusion criteria were tumor invasion into the gastrointestinal tract or a major blood vessel, uncontrolled infection, early recurrence (<3 months), and severe concomitant diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00181DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445888PMC
March 2019
2 Reads

Application of plasma circulating cell-free DNA detection to the molecular diagnosis of hepatocellular carcinoma.

Am J Transl Res 2019 15;11(3):1428-1445. Epub 2019 Mar 15.

Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing Key Laboratory of Emerging Infectious Diseases Beijing 100015, China.

Circulating tumor DNA (ctDNA) carries genetic information consistent with tumor cells and has potential value for molecular diagnosis of tumors. The present study analysed the gene mutations of plasma circulating cell-free DNA (cfDNA) and tumor tissue DNA in hepatocellular carcinoma (HCC) patients and explored the clinical application value of plasma cfDNA as a tumor marker in HCC molecular diagnosis. Samples from 29 patients with primary HCC were collected. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456549PMC
March 2019
1 Read

Long noncoding RNA EPB41L4A-AS2 inhibits hepatocellular carcinoma development by sponging miR-301a-5p and targeting FOXL1.

J Exp Clin Cancer Res 2019 Apr 10;38(1):153. Epub 2019 Apr 10.

Department of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.

Background: Hepatocellular carcinoma (HCC) is the major histological type of liver cancer with high morbidity and mortality worldwide. Long noncoding RNAs (lncRNA) has been proved to be associated with various cancer types, while its regulation in HCC is largely unknown.

Methods: To figure out the specific role of lncRNA EPB41L4A-AS2 in HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-019-1128-9DOI Listing
April 2019
1 Read

Primary hepatic follicular dendritic cell sarcoma: A case report.

World J Clin Cases 2019 Mar;7(6):785-791

Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.

Background: Follicular dendritic cell sarcoma (FDCS) is an uncommon type of tumor with low incidence. To date, no standard treatment for the disease has been established. Surgery remains the main treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12998/wjcc.v7.i6.785DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448081PMC
March 2019
1 Read

Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected Patients on Tenofovir therapy: Relevance for Screening Strategies.

J Hepatol 2019 Apr 6. Epub 2019 Apr 6.

Department of Infectious Diseases, Bern University Hospital, University of Bern, Switzerland.

Background And Aims: Robust data on hepatocellular carcinoma (HCC) incidence among HIV/hepatitis B virus (HBV)-coinfected individuals on antiretroviral therapy (ART) are needed to inform HCC screening strategies. We aimed to evaluate the incidence and risk factors of HCC among HIV/HBV-coinfected individuals on tenofovir disoproxil fumarate (TDF)-containing ART in a large multi-cohort study.

Methods: We included all HIV-infected adults with a positive hepatitis B surface antigen followed in one of four prospective European cohorts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.03.032DOI Listing
April 2019
2 Reads

Pretreatment risk management of a novel nomogram model for prediction of thoracoabdominal extrahepatic metastasis in primary hepatic carcinoma.

J Transl Med 2019 Apr 8;17(1):117. Epub 2019 Apr 8.

Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, 17 Yongwai Zheng Street, Nanchang, 330006, China.

Background: Extrahepatic metastasis is the independent risk factor of poor survival of primary hepatic carcinoma (PHC), and most occurs in the chest and abdomen. Currently, there is still no available method to predict thoracoabdominal extrahepatic metastasis in PHC. In this study, a novel nomogram model was developed and validated for prediction of thoracoabdominal extrahepatic metastasis in PHC, thereby conducted individualized risk management for pretreatment different risk population. Read More

View Article

Download full-text PDF

Source
https://translational-medicine.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s12967-019-1861-zDOI Listing
April 2019
2 Reads

Liver transplantation with a normothermic machine preserved fatty nonagenarian liver: A case report.

Int J Surg Case Rep 2019 Mar 30;57:163-166. Epub 2019 Mar 30.

Department of Surgery, HPB and Transplant Unit, Tor Vergata University of Rome, Italy.

Introduction: The use of organs from expanded criteria donors for Liver Transplantation (LT) represents a major challenge. In the current era of Normothermic Machine Perfusion (NMP), donor age boundaries are often overcome and may contribute to reduce the gap between supply and demand of organs suitable for transplantation. We report on a unique case of nonagenarian liver successfully transplanted after NMP. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22102612193015
Publisher Site
http://dx.doi.org/10.1016/j.ijscr.2019.03.033DOI Listing
March 2019
2 Reads

A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors.

Int J Cancer 2019 Apr 8. Epub 2019 Apr 8.

University of Southern California/Norris Comprehensive Center, Los Angeles, CA.

Regorafenib 160 mg orally once daily (QD) 3 weeks on/1 week off is approved in colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma. We established the safety and pharmacokinetics (PK) of regorafenib combined with cetuximab in advanced refractory solid tumors. This was a phase 1, open-label, dose-escalation study (NCT01973868) in patients with advanced/metastatic solid tumors who progressed after standard therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32317DOI Listing
April 2019
1 Read

Increasing incidence and mortality related to liver cancer in Australia: time to turn the tide.

Aust N Z J Public Health 2019 Apr 8. Epub 2019 Apr 8.

Menzies Institute for Medical Research, University of Tasmania.

Objective: Assess national and jurisdictional incidence and mortality trends for primary liver cancer in Australia.

Methods: Analysis of Australian Cancer Incidence and Mortality data published in 2017 by the AIHW. Age-standardised rates (ASR) for 1982 to 2014/2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1753-6405.12889DOI Listing
April 2019
1 Read

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.

Lancet Gastroenterol Hepatol 2019 Apr 3. Epub 2019 Apr 3.

Onxeo, Paris, France.

Background: Cytotoxic chemotherapy is generally ineffective in patients with hepatocellular carcinoma. We assessed the intravenous perfusion of doxorubicin-loaded nanoparticles in patients with hepatocellular carcinoma in whom previous sorafenib therapy had failed.

Methods: We did a multicentre, open-label, randomised, controlled phase 3 trial at 70 sites in 11 countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2468-1253(19)30040-8DOI Listing
April 2019
1 Read

I seed implantation for hepatocellular carcinoma with portal vein tumor thrombus: A systematic review and meta-analysis.

Brachytherapy 2019 Apr 3. Epub 2019 Apr 3.

Department of oncology, Hebei General Hospital, Shijiazhuang, Hebei, China. Electronic address:

Purpose: Advanced hepatocellular carcinoma often combined with portal vein tumor thrombus (PVTT), transcatheter arterial chemoembolization (TACE) is recommended as an effective treatment. Recent studies showed that TACE plus iodine-125 (I) seed for hepatocellular carcinoma with PVTT can improve the remission rate. This study aimed to systematically evaluate the efficacy and safety of I seed implantation in patients with PVTT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2019.01.014DOI Listing
April 2019
2 Reads

ANXA2 and FLNA phosphorylation associate with poor prognosis in hepatic carcinoma revealed by quantitative phosphoproteomics analysis.

J Proteomics 2019 Apr 2;200:111-122. Epub 2019 Apr 2.

The School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350004, People's Republic of China. Electronic address:

Hepatoma is one of the most common malignant tumors, and most patients have very poor prognosis. Early prediction and intervention of the hepatoma recurrence/metastasis are the most effective way to improve the patients' clinical outcomes. Here, we used isobaric tags for relative and absolute quantitation (iTRAQ) based quantitative phospho-proteomics approach to identify biomarkers associated with hepatoma recurrence/metastasis in hepatoma cell lines with increasing metastasis ability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jprot.2019.03.017DOI Listing
April 2019
3 Reads

Accuracy of Pretransplant Imaging Diagnostic for Hepatocellular Carcinoma: A Retrospective German Multicenter Study.

Can J Gastroenterol Hepatol 2019 5;2019:8747438. Epub 2019 Mar 5.

Department of Hepatobiliary and Transplant Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Selection and prioritization of patients with HCC for LT are based on pretransplant imaging diagnostic, taking the risk of incorrect diagnosis. According to the German waitlist guidelines, imaging has to be reported to the allocation organization (Eurotransplant) and pathology reports have to be submitted thereafter. In order to assess current procedures we performed a retrospective multicenter analysis in all German transplant centers with focus on accuracy of imaging diagnostic and tumor classification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/8747438DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425358PMC
March 2019
1 Read

Expression and significance of LncRNA-MINCR and CDK2 mRNA in primary hepatocellular carcinoma.

Comb Chem High Throughput Screen 2019 Apr 4. Epub 2019 Apr 4.

Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003. China.

Objective: To investigate the expression of long-chain non-coding RNA MINCR (LncRNA-MINCR) and cyclin-dependent kinase 2 (CDK2) mRNA in primary hepatocellular carcinoma, and to analyze the relationship between its expression and clinical pathological parameters and prognosis of hepatocellular carcinoma.

Methods: Seventy-five surgically resected primary hepatocellular carcinoma tissues and paracancerous tissues were selected. Real-time PCR was used to detect the expression of LncRNA-MINCR and CDK2 mRNA in hepatocellular carcinoma tissues and adjacent tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1386207322666190404151020DOI Listing
April 2019
6 Reads

Sorafenib alone vs. sorafenib plus GEMOX as 1-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial.

Br J Cancer 2019 Apr 4. Epub 2019 Apr 4.

Gustave Roussy, Villejuif, France.

Background: Sorafenib remains one major first-line therapeutic options for advanced hepatocellular carcinoma (aHCC), with modest efficacy. We investigated the addition of gemcitabine and oxaliplatin (GEMOX) to sorafenib in aHCC patients.

Methods: Our multicentre phase II trial randomised aHCC first-line patients to sorafenib (400 mg BID) or sorafenib-GEMOX every 2 weeks (1000 mg/m gemcitabine; 100 mg/m oxaliplatin). Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41416-019-0443-4
Publisher Site
http://dx.doi.org/10.1038/s41416-019-0443-4DOI Listing
April 2019
5 Reads

Porphyria cutanea tarda increases risk of hepatocellular carcinoma and premature death: a nationwide cohort study.

Orphanet J Rare Dis 2019 Apr 3;14(1):77. Epub 2019 Apr 3.

Norwegian Quality Improvement of Laboratory Examinations (NOKLUS), Haraldsplass Deaconess Hospital, Bergen, Norway.

Background: Porphyria cutanea tarda (PCT) is a skin disorder originating from a deficit of the liver enzyme uroporphyrinogen decarboxylase. PCT may be a risk factor for hepatocellular carcinoma (HCC) and other cancers, but the evidence is unclear. We aimed to investigate cancer and premature mortality risk in persons with PCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13023-019-1051-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448269PMC
April 2019
2 Reads

Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.

PLoS One 2019 3;14(4):e0214387. Epub 2019 Apr 3.

The Nutrition Program, School of Biological and Population Health Sciences, Oregon State University, Corvallis, Oregon, United States of America.

Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, particularly in obese and type 2 diabetic individuals. NAFLD ranges in severity from benign steatosis to nonalcoholic steatohepatitis (NASH); and NASH can progress to cirrhosis, primary hepatocellular carcinoma (HCC) and liver failure. As such, NAFLD has emerged as a major public health concern. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0214387PLOS
April 2019
3 Reads

Short-term efficacy of oral low-dose Tegafur chemotherapy after transarterial chemoembolization in primary hepatic carcinoma.

J BUON 2019 Jan-Feb;24(1):171-177

Integrated Treatment Room, the Second Xiangya Hospital of Central Sounth University, Changsha, China.

Purpose: To observe the short-term efficacy of oral low-dose Tegafur chemotherapy after transarterial chemoembolization (TACE) in primary hepatic carcinoma (PHC).

Methods: 120 PHC patients undergoing TACE treatment for the first were randomly divided into the Tegafur group and the TACE group. Patients in TACE group received TACE only, whereas those in the Tegafur group received TACE and postoperative oral low-dose Tegafur chemotherapy. Read More

View Article

Download full-text PDF

Source
April 2019
4 Reads

Analysis on efficacy and safety of TACE in combination with RFA and MWA in the treatment of middle and large primary hepatic carcinoma.

J BUON 2019 Jan-Feb;24(1):163-170

Department of intervention, Jianhu County People's Hospital, Jianhu, Jiangsu 224700, China.

Purpose: To compare and explore the efficacy and safety of transcatheter arterial chemoembolization (TACE) in combination with radiofrequency ablation (RFA) and microwave ablation (MWA) in the treatment of middle and large primary hepatic carcinoma.

Methods: A retrospective analysis was made on 75 patients with middle and large hepatic carcinoma (tumor diameter ≥3 cm) receiving TACE in combination with thermal ablation therapy in our hospital from January 2012 to January 2015, with hepatic function Child-Pugh class A and B. Forty-one cases received TACE+RFA, while 34 cases received TACE+MWA. Read More

View Article

Download full-text PDF

Source
April 2019
4 Reads

Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B.

Cochrane Database Syst Rev 2019 Apr 3;4:CD013089. Epub 2019 Apr 3.

Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Bei San Huan Dong Lu 11, Chaoyang District, Beijing, China, 100029.

Background: Hepatitis B virus (HBV) infection, a liver disease caused by hepatitis B virus, may lead to serious complications such as cirrhosis and hepatocellular carcinoma. People with HBV infection may have co-infections including HIV and other hepatitis viruses (hepatitis C or D), and co-infection may increase the risk of all-cause mortality. Chronic HBV infection increases morbidity and psychological stress and is an economic burden on people with chronic hepatitis B and their families. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD013089.pub2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446139PMC
April 2019
2 Reads

Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma.

J Gastroenterol 2019 Apr 2. Epub 2019 Apr 2.

The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1, Kohnodai, Ichikawa, Chiba, 272-8516, Japan.

Background: Cancer-associated fibroblasts (CAFs) are essential constituents of cancer-supportive microenvironments. The high incidence of hepatocellular carcinoma (HCC) in advanced fibrosis patients implies that fibroblasts have a promoting effect on HCC development. We aimed to explore the regulators of phenotypes and function of CAFs in the liver. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00535-019-01579-5DOI Listing
April 2019
4 Reads

Anticancer effects of Gleditsia sinensis extract in rats transplanted with hepatocellular carcinoma cells.

Oncol Res 2019 Apr 2. Epub 2019 Apr 2.

Infectious disease of Wuhan Medical Treatment Center, Wuhan 430040, China.

The thorns of have been historically used in Chinese medicine, and considered one of the fundamental therapeutic herbs. Its anticancer effects are currently being explored. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and still requires the development of new drugs with higher efficiency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3727/096504018X15482423944678DOI Listing
April 2019
3 Reads

Inhibition of the chimeric DnaJ-PKAc enzyme by endogenous inhibitor proteins.

J Cell Biochem 2019 Apr 2. Epub 2019 Apr 2.

University of Vermont Cancer Center, Burlington, Vermont.

The chimeric DnaJ-PKAc enzymeresulting from an approximately 400-kb deletion of chromosome 19 is a primary contributor to the oncogenic transformation that occurs in fibrolamellar hepatocellular carcinoma, also called fibrolamellar carcinoma (FLC). This oncogenic deletion juxtaposes exon 1 of the DNAJB1 heat shock protein gene with exon 2 of the PRKACA gene encoding the protein kinase A catalytic subunit, resulting in DnaJ-PKAc fusion under the transcriptional control of the DNAJB1 promoter. The expression of DnaJ-PKAc is approximately 10 times that of wild-type (wt) PKAc catalytic subunits, causing elevated and dysregulated kinase activity that contributes to oncogenic transformation. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/jcb.28651
Publisher Site
http://dx.doi.org/10.1002/jcb.28651DOI Listing
April 2019
5 Reads

Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma.

Radiother Oncol 2019 Apr 16;133:54-61. Epub 2019 Jan 16.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States. Electronic address:

Background And Purpose: This study documents the utilization and efficacy of proton beam therapy (PBT) in western patients with localized unresectable hepatocellular carcinoma (HCC).

Methods And Methods: Forty-six patients with HCC, Child-Pugh class of A or B, no prior radiotherapy history, and ECOG performance status 0-2 received PBT at our institution from 2007 to 2016. Radiographic control within the PBT field (local control, LC) and overall survival (OS) were calculated from the start of PBT. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01678140183367
Publisher Site
http://dx.doi.org/10.1016/j.radonc.2018.10.041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446916PMC
April 2019
2 Reads

Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.

BMC Cancer 2019 Apr 1;19(1):292. Epub 2019 Apr 1.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro, 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.

Background: Although sorafenib is the global standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC), it does not have reliable predictive or prognostic biomarkers. Circulating cell-free DNA (cfDNA) has shown promise as a biomarker for various cancers. We investigated the use of cfDNA to predict clinical outcomes in HCC patients treated with sorafenib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5483-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444867PMC
April 2019
2 Reads
3.362 Impact Factor

Successful recanalization of acute extensive portal vein thrombosis by aspiration thrombectomy and thrombolysis via an operatively placed mesenteric catheter: a case report.

BJR Case Rep 2018 Dec 21;4(4):20180024. Epub 2018 May 21.

Department of Radiology, Tokyo Medical University Hospital, Tokyo, Japan.

Portal vein thrombosis (PVT) after hepatobiliary surgery is rare but can cause lethal and severe complications. If early diagnosis and recanalization can be achieved, the PVT is expected to be eliminated. A 70-year-old male was diagnosed as having hepatocellular carcinoma occupying the right lobe of the liver. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1259/bjrcr.20180022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438407PMC
December 2018
1 Read

Inhibition of PSMD4 blocks the tumorigenesis of hepatocellular carcinoma.

Gene 2019 Mar 28;702:66-74. Epub 2019 Mar 28.

Department of Gastroenterology, Qilu Hospital of Shandong University, China. Electronic address:

Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver with high mortality and frequent recurrence. Although various therapies provide potential cure for HCC patients, unfortunately the five-year survival rate of advanced HCC remains dismal. It is critical to explore the pathogenesis of HCC and identify novel biomarkers for early HCC diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gene.2019.03.063DOI Listing
March 2019
2 Reads

[Progress on surgical treatment of intrahepatic cholangiocarcinoma].

Zhonghua Wai Ke Za Zhi 2019 Apr;57(4):241-246

Department of Hepatic Surgery IV, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai 200433, China.

Intrahepatic cholangiocarcinoma(ICC)is a primary liver cancer with its incidence only after hepatocellular carcinoma.Liver resection is currently the only established effective treatment for patients with ICC.However,the resectability of ICC is low and the long-term survival after surgery is far from satisfactory. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0529-5815.2019.04.001DOI Listing
April 2019
1 Read

Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial.

BMC Cancer 2019 Mar 28;19(1):275. Epub 2019 Mar 28.

Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 2, Min-Sheng Road, Dalin, Chia-Yi, Taiwan, Republic of China.

Background: Hepatocellular carcinoma (HCC) accounts for 75-85% of primary liver cancers and is prevalent in the Asia-Pacific region. Till now, trans-arterial chemoembolization (TACE) is still one of common modalities in managing unresectable intermediate-stage HCC. However, post-TACE residual viable HCC is not uncommon, resulting in unsatisfied overall survival after TACE alone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5461-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437913PMC
March 2019
1 Read

First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers.

BMC Cancer 2019 Mar 28;19(1):279. Epub 2019 Mar 28.

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.

Background: With poor prognosis and limited treatment options for advanced hepatocellular carcinoma (HCC), development of novel therapeutic agents is urgently needed. This single-arm phase I study sought to assess the safety and preliminary efficacy of icaritin in human as a potential oral immunotherapy in addition to the immune-checkpoint inhibitors.

Methods: Eligible advanced HCC patients with Child-Pugh Class A or B were administered with a fixed oral dose of icaritin at either 600 or 800 mg b. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5471-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437929PMC
March 2019
1 Read

The clinical significance of microRNA-122 in predicting the prognosis of patients with hepatocellular carcinoma: A meta-analysis validated by the Cancer Genome Atlas dataset.

Medicine (Baltimore) 2019 Mar;98(13):e14810

Department of Infectious Diseases, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.

Background: Although the prognostic value of microRNA-122 (miR-122) for hepatocellular carcinoma (HCC) patients have been evaluated by numerous studies, the results of them were not completely consistent. The present study aims to comprehensively evaluate the predicting value of miR-122 on the prognosis of patients with HCC based on all eligible literatures.

Methods: Numerous electronic databases (MEDLINE, Embase, Pubmed, Google Scholar, and China Biology Medicine disc) were applied to retrieve relevant studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014810DOI Listing
March 2019
1 Read
5.723 Impact Factor

The long noncoding RNA cardiac hypertrophy-related factor plays oncogenic roles in hepatocellular carcinoma by downregulating microRNA-211.

J Cell Biochem 2019 Mar 27. Epub 2019 Mar 27.

Department of Hepatobiliary Surgery, Jining No.1 People's Hospital, Jining, Shandong, China.

Background: Hepatocellular carcinoma (HCC) is the most major type of primary hepatic cancer. This study aimed to explore the possible oncogenic effects of the long noncoding RNA cardiac hypertrophy-related factor (CHRF) on HCC, as well as the underlying possible mechanism.

Methods: The expression levels of CHRF and microRNA-211 (miR-211) in HCC tissues and/or cell lines HepG2 and Huh-7 were measured using quantitative reverse transcription polymerase chain reaction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.28611DOI Listing
March 2019
1 Read

MiR-888 promotes cell migration and invasion of hepatocellular carcinoma by targeting SMAD4.

Eur Rev Med Pharmacol Sci 2019 Mar;23(5):2020-2027

Department of Blood Transfusion, Yantai Yuhuangding Hospital, Yantai, China.

Objective: Hepatocellular carcinoma (HCC), a type of primary liver cancer, is the second leading cause of cancer mortality worldwide. Increasing evidence suggests that dysfunction of microRNAs (miRNAs) plays an important role in human cancers. MicroRNA-888 (miR-888) has been reported to be upregulated in multiple cancers that have a high rate of metastasis. Read More

View Article

Download full-text PDF

Source
http://www.europeanreview.org/article/17241
Publisher Site
http://dx.doi.org/10.26355/eurrev_201903_17241DOI Listing
March 2019
10 Reads

Remodelling and Improvements in Organoid Technology to Study Liver Carcinogenesis in a Dish.

Stem Cells Int 2019 19;2019:3831213. Epub 2019 Feb 19.

Department of Internal Medicine I, Ulm University, Ulm, Germany.

Primary liver cancer (PLC) is the sixth most common tumour disease and one of the leading causes of cancer-related death worldwide. The two most common types of PLC are hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). Diverse subgroups are described and a manifold number of gene mutations are known. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/3831213DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399527PMC
February 2019
1 Read

[A Resected Case of Reactive Lymphoid Hyperplasia of the Liver Preoperatively Diagnosed as Hepatocellular Carcinoma].

Gan To Kagaku Ryoho 2019 Mar;46(3):540-542

Dept. of Surgery, Toyonaka Municipal Hospital.

A60s woman was followed-up regularly for primary biliary cholangitis and a solitary enlarging hepatic mass in the S6 segment of her liver was discovered by ultrasonography. We diagnosed the mass as hepatocellular carcinoma by contrast ultrasonography, contrast computed tomography, and ethoxbenzyl magnetic resonance imaging and laparoscopic partial hepatectomy of S6 segment was performed. The resected specimen was histopathologicaly diagnosed as liver-reactive lymphoid hyperplasia(RLH). Read More

View Article

Download full-text PDF

Source
March 2019
2 Reads

Prevention of Hepatocellular Carcinoma by Statins: Clinical Evidence and Plausible Mechanisms.

Semin Liver Dis 2019 Mar 25. Epub 2019 Mar 25.

Department of Internal Medicine, Yonsei University College of Medicine, Yonsei University, Seoul, Republic of Korea.

Statins, or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are widely used to treat hypercholesterolemia for primary and secondary prevention of cardiovascular disease. Statins inhibit HMG-CoA reductase, the rate-limiting step in cholesterol synthesis, and modulate the downstream signaling of the mevalonate pathway. In addition to the primary effect, the antitumor effect of statins can be associated with mevalonate pathway-mediated and nonmevalonate pathway-mediated mechanisms, which improve endothelial function and lead to proapoptotic, antiproliferative, antiinflammatory, and antifibrotic properties. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0039-1679956DOI Listing
March 2019
1 Read

Engagement with tNOX (ENOX2) to Inhibit SIRT1 and Activate p53-Dependent and -Independent Apoptotic Pathways by Novel 4,11-Diaminoanthra[2,3-]furan-5,10-diones in Hepatocellular Carcinoma Cells.

Cancers (Basel) 2019 Mar 24;11(3). Epub 2019 Mar 24.

tian Hospital, Changhua 50008, Taiwan.

Hepatocellular carcinoma (HCC) is the most frequent primary malignancy of the liver and is among the top three causes of cancer-associated death worldwide. However, the clinical use of chemotherapy for HCC has been limited by various challenges, emphasizing the urgent need for novel agents with improved anticancer properties. We recently synthesized and characterized a series of 4,11-diaminoanthra[2,3-]furan-5,10-dione derivatives that exhibit potent apoptotic activity against an array of cancer cell lines, including variants with multidrug resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11030420DOI Listing
March 2019
1 Read

Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach.

Int J Mol Sci 2019 Mar 22;20(6). Epub 2019 Mar 22.

Department of Surgery and Transplantation, University Hospital RWTH Aachen, 52074 Aachen, Germany.

Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and its mortality is third among all solid tumors, behind carcinomas of the lung and the colon. Despite continuous advancements in the management of this disease, the prognosis for HCC remains inferior compared to other tumor entities. While orthotopic liver transplantation (OLT) and surgical resection are the only two curative treatment options, OLT remains the best treatment strategy as it not only removes the tumor but cures the underlying liver disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20061465DOI Listing
March 2019
1 Read